|
|
Effects of Using Recombinant Human Interferon α2b Gel in Combination with Azithromycin in Patients with Chronic Cervicitis Accompanied by HPV Infection |
XIE Fei, LI Shuang |
Department of Pharmacy,XD Group Hospital, Xi'an Shaanxi 710077 |
|
|
Abstract 【Objective】To explore the application effect of recombinant human interferon α2b gel combined with azithromycin in patients with chronic cervicitis with HPV infection. 【Methods】A total of 110 patients with chronic cervicitis with HPV infection who were admitted to the XD Group Hospital from March 2021 to March 2023 were selected as the research objects. They were divided into the control group and the observation group by random number table method, with 55 cases in each group. The control group was treated with recombinant human interferon α2b gel, while the observation group was treated with recombinant human interferon α2b gel combined with azithromycin. Both treatments were for a course of 2 weeks. The clinical efficacy, Lactobacillus reduction rate, leukocyte esterase (LE) test and coagulase (GADP), vaginal pH value, inflammation factors [tumor necrosis factor-α (TNF-α), interleukin-1β(IL-1β), interleukin-8(IL-8)]level, HPV virus load, conversion rate, and recurrence rate of the two groups were compared. 【Results】The total effective rate of the study group was higher than that of the control group, and the difference was statistically significant (P<0.05). The reduction rate of Lactobacillus, positive rate of LE, positive rate of GADP, and proportion of vaginal pH value >4.5 in the observation group were all higher than those in the control group, and the differences were statistically significant (P<0.05). Before treatment, there was no statistical significance in the comparison of inflammation factors between the two groups (P>0.05). After treatment, the levels of TNF-α, IL-1β, and IL-8 in the observation group were lower than those in the control group, the difference was statistically significant (P<0.05). After treatment, the virus load of both groups decreased, while the virus load of the observation group was lower than that of the control group, and the difference was statistically significant (P<0.05). The HPV negative conversion rate of the observation group was higher than that of the control group, the HPV recurrence rate and the disease recurrence rate in the observation were lower than those in the control group, and the differences were statistically significant (P<0.05). 【Conclusion】Recombinant human interferon α2b gel combined with azithromycin has significant effects in patients with chronic cervicitis with HPV infection. It can reduce inflammation, reduce HPV virus load, promote HPV negative conversion, which is worth promoting.
|
Received: 30 June 2023
|
|
|
|
|
[1] 马艳芬,毕颖,陈艳玲. 重组人IFNα2b凝胶联合冷冻治疗老年慢性宫颈炎合并HPV感染的临床疗效及对IL-12、IFN-γ、IL-4、IL-10水平的影响[J].中国老年学杂志,2023,43(8):1872-1875. [2] 何晶,张烽,朱佳尔. 抗HPV生物蛋白敷料与重组人干扰素α-2b凝胶治疗高危型HPV感染的研究[J].中华医院感染学杂志,2020,30(3):403-408. [3] 吕小可,陈莉,代雪莹. 阿奇霉素与保妇康栓联用对慢性宫颈炎伴HPV感染的结局影响[J].贵州医药,2021,45(9):1419-1420. [4] 谢幸,苟文丽.妇产科学[M].8版.北京:人民卫生出版社,2013:255-256. [5] 孙传兴.临床疾病诊断依据治愈好转标准[M].北京:人民军医出版社,2002: 530-531. [6] 张海琴,刘娟娟,娄俊丽,等. 慢性宫颈炎患者HPV感染状况、基因型分布及其与阴道微生态指标的相关性研究[J].海南医学,2022,33(4):464-467. [7] 龚娅,段德令,史秋霞,等. 阴道分泌物功能酶检测联合常规镜检在阴道微生态改变中的应用价值[J].国际检验医学杂志,2019,40(20):2491-2493. [8] 周茜. COOK双球囊联合缩宫素对妊娠晚期产妇宫颈成熟度、引产效果及血清TNF-α、IL-8和IL-1β水平的影响[J].中国现代医药杂志,2022,24(1):43-47. [9] 李莉,朱颖军,高静,等. CKC联合重组人干扰素α-2 b凝胶治疗宫颈上皮内瘤变Ⅱ级疗效及预后影响因素分析[J].中国计划生育学杂志,2022,30(10):2213-2217. [10] 李倩,李瑞平,王琳琳. AV/BV五联检阴道微生态异常与高危型HPV感染的相关性分析[J].中国处方药,2020,18(4):173-174. [11] 韦彩素,陈慧峰,李建湘,等. 子宫颈病变患者阴道微生态环境与HR-HPV感染的相关性及子宫颈病变的影响因素分析[J].中外医学研究,2021,19(17):4-7. [12] 王晓东. 阿奇霉素与保妇康栓联用对慢性宫颈炎伴HPV感染LEEP术后预后及复发的影响[J].泰山医学院学报,2020,41(4):269-271. [13] 常玉梅,张凤喜,王薇,等. 复方沙棘籽油栓联合重组人干扰素α2b凝胶治疗慢性宫颈炎合并高危型人乳头瘤病毒感染疗效观察[J].河北中医,2021,43(6):969-971. [14] 周蕊,高艳红,田梦蝶. 抗宫炎片联合重组人干扰素α2b凝胶治疗慢性宫颈炎的效果[J].中国医药导报,2020,17(8):97-100. [15] 董鹂芸,张晴,韩变利. 清热化湿解毒汤联合重组人干扰素α-2b治疗宫颈炎合并HPV感染患者的效果[J].海南医学,2022,33(8):1020-1023. [16] 李淑华,杨焱,余受益. 妇科排毒汤联合西药治疗慢性宫颈炎合并HPV感染的疗效及对病毒载量的影响[J].世界中西医结合杂志,2021,16(7):1279-1283. |
[1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2023, 40(3): 438-440. |
|
|
|
|